#United States #New York #Securities Fraud #Pomerantz LLP #Keros Therapeutics

Investigation into Keros Therapeutics, Inc.

The recent revelation from the Pomerantz Law Firm, which specializes in corporate and securities class litigation, has brought Keros Therapeutics, Inc. under scrutiny as it investigates claims of possible securities fraud. Investors are encouraged to reach out to the firm for information regarding their potential inclusion in this investigation.

Keros Therapeutics (NASDAQ: KROS) has been experiencing significant turbulence in its stock prices due to safety concerns linked to its ongoing clinical trials for its treatment, cibotercept (KER-012).

The Timeline of Events

On December 12, 2024, Keros disclosed a voluntary halt in its dosing regimen for specific treatment arms in the TROPOS trial, which is pivotal in exploring the effects of cibotercept in patients suffering from pulmonary arterial hypertension (PAH). This decision was prompted by the unanticipated observation of pericardial effusion, a concerning adverse event noted during the trial. As a direct consequence of this grim announcement, Keros's stock plummeted by over 73%, collapsing the share price from $68.65 to $18.43.

The situation worsened for investors when, on January 15, 2025, Keros announced a total cessation of dosing in the TROPOS trial, citing further adverse events and ongoing safety reviews. Following this disclosure, Keros’s stock experienced an additional downturn, falling 16.51% to close at $10.42.

The Investigation

As investors grapple with the substantial losses incurred, Pomerantz LLP is investigating whether Keros, alongside its officers and directors, engaged in practices that may violate securities regulations or defraud stakeholders. The firm has established a platform for impacted investors to participate in a class action lawsuit aimed at defending their rights against potential corporate misconduct.

Pomerantz’s Legacy

Established by the late Abraham L. Pomerantz, the firm is highly regarded as a pioneer in the realm of securities class actions. Over its 85-year history, Pomerantz has fought vigorously for the rights of individuals wronged by corporate fraud, successfully recovering numerous multi-million dollar settlements for class members. The firm operates from major cities including New York, Chicago, and Los Angeles, continuing the tradition of advocating for justice in the corporate world.

Conclusion

The spotlight is now on Keros Therapeutics as it deals with the ramifications of its recent decisions and the ensuing investigation. Investors with queries or who may wish to contribute to the class action are urged to contact Pomerantz LLP directly. As the situation unfolds, the focus remains on ensuring accountability and justice for those affected by the alleged misconduct.

For more details or to express your concerns, reach out to Danielle Peyton at Pomerantz LLP at [email protected] or 646-581-9980, ext. 7980.